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Several animal models of Alzheimer’s disease have been used in laboratory experiments. Intrahippocampal injection of fibrillar
amyloid-beta (fA𝛽) peptide represents one of the most frequently used models, mimicking A𝛽 deposits in the brain. In our
experiment synthetic fA𝛽
1−42
peptide was administered to rat hippocampus. The effect of the A𝛽 peptide on spatial memory and
dendritic spine density was studied. The fA𝛽
1−42
-treated rats showed decreased spatial learning ability measured in Morris water
maze (MWM). Simultaneously, fA𝛽
1−42
caused a significant reduction of the dendritic spine density in the rat hippocampus CA1
region.The decrease of learning ability and the loss of spine density were in good correlation. Our results prove that both methods
(MWM and dendritic spine density measurement) are suitable for studying A𝛽-triggered neurodegeneration processes.
1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder characterized by deficit of learning process,
severe memory loss, and complex behavioural changes [1–
5]. Neuropathological hallmarks of AD include the cerebral
accumulation of extracellular senile plaques containing vari-
ous forms of amyloid-beta (A𝛽) peptide assemblies and the
presence of intracellular neurofibrillary tangles containing
tau protein [6–8]. Other features of AD are neuroinflam-
mation, cerebrovascular alterations, activated astrocytes, and
microglia as well as synaptic and neuronal loss in specific
brain regions [9–11]. The affected brain regions are forebrain
and medial temporal lobe structures like the hippocampus
(HC), the entorhinal cortex, and the amygdala [11]. Synapse
loss is strongly correlated with cognitive impairment; thus
synapse number is the best indicator of cognitive decline
in AD [1, 12]. The senile plaques are associated with local
synapse and dendritic spine loss [13, 14]. Moreover, the
fibrillar deposits are surrounded by a halo of oligomeric
A𝛽 assemblies [15]. Extracellular oligomeric A𝛽 associates
with dendritic spines covering their surface [15]. In addition,
intracellular A𝛽 may also contribute to AD pathology by
tau hyperphosphorylation and synaptic dysfunction [16].The
toxic effects of different aggregation forms of A𝛽 (oligomers,
protofibrils, and fibrils) have not been revealed completely
yet.
Dendritic spines are cellular compartments containing
the molecular machinery important for synaptic trans-
mission and plasticity [17]. In pyramidal neurons of the
hippocampus, there is an almost one-to-one relationship
between the number of dendritic spines and excitatory
synapses [17, 18].The loss of dendritic spines and the presence
of dystrophic neurites have been reported both in the amyloid
precursor protein (APP) overexpressing transgenic mouse
model of AD and in the AD-affected human brain [2, 8, 19,
20]. The spine density of prefrontal cortex neurons is greatly
reduced in aged monkeys as a hallmark of cognitive decline
[21]. Neurocortical pyramidal neurons have extensive apical
and basilar dendritic trees to integrate information from
excitatory and inhibitory synaptic inputs. In the neuronal
network, dendritic spines represent the principal receptive
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sites for the excitatory inputs to the neurons. The strength,
stability, and function of the excitatory synaptic connec-
tions constitute the basis of cognitive function [22]. In
the cerebral cortex of mammals, the rapid synaptogenesis
during early postnatal life is followed by a substantial loss
of synapses/spines that extends through adolescence. In
adulthood, the number of spines remains relatively stable
and then decreases progressively with aging [22, 23]. Spines
appear and disappear through life, but their turnover rate
declines with the age and is regulated by the neuronal activity
[18]. Dendritic spines undergo structural modifications when
the synaptic strength is experimentally modified (e.g., by
evoking long-term potentiation or long-term depression) [18,
22, 24].
Extracellular delivery of A𝛽 peptides can initiate synaptic
loss in rodent brains [25]. Intrahippocampal (IHC) admin-
istration of A𝛽 is a widely used animal model to study AD
[4, 25–38]. The injection of A𝛽 into murine brain rapidly
establishes the symptoms of AD. This method is suitable
for studying the effects of the different aggregates of A𝛽.
There are conflicting results about the neurotoxicity of 𝛽-
amyloid plaque depositions [39]; however, the toxic effect of
A𝛽 peptides on synapses has been widely acknowledged.
Reduction of dendritic spine density has been shown in
cell cultures after A𝛽 treatment [40–43]. Furthermore, IHC
administration of fibrillar A𝛽
1−40
has been shown to decrease
spine density [25, 28]. Interestingly, no experiments have
been performed using well characterized A𝛽
1−42
, the most
toxic form of A𝛽 peptides. Thus the aim of this study was to
assess the impact of fibrillar A𝛽
1−42
(fA𝛽
1−42
) administration
on spatial memory of rats and dendritic spine density in the
hippocampus. Our hypothesis was that IHC injected syn-
thetic, fibrillar formofA𝛽
1−42
could simultaneously influence
and reduce the learning process and dendritic spine density.
Since hippocampal dendritic spines are the key elements
in acquisition and retention and have been implicated in
learning and memory processes [44, 45], we also compared
the correlation between the changes of dendritic spine density
(induced by fA𝛽
1−42
administration) and the spatial memory
of rats.
2. Materials and Methods
2.1. Animals. Male Charles-River Wistar rats (𝑛 = 24),
weighing about 210–230 g at the beginning of the experiment,
were used as subjects. Two groups, control (𝑛 = 12) and
fA𝛽
1−42
-treated (𝑛 = 12), were formed. They were housed in
groups of three under constant temperature, humidity, and
lighting conditions (23∘C, 12 : 12 h light/dark cycle, lights on
at 7 a.m.). Standard rat chow and tap water were supplied ad
libitum. All behavioural procedures were conducted during
the light phase. Handling was done daily at the same time.
Experiments were performed in accordance with the Euro-
pean Communities Council Directive of 22 September 2010
(2010/63/EU on the protection of animals used for scientific
purposes). Formal approval to conduct the experiments was
obtained from the Animal Experimentation Committee of
the University of Szeged.
Figure 1: Representative electron microscope photomicrograph of
the injected amyloid-beta fibrils.
2.2. Synthesis of A𝛽
1−42
and Preparation of the Fibrillar
Peptide Aggregates. The synthesis was performed as reported
earlier in Bozso et al. [46]. The fA𝛽
1−42
was prepared as
described by He et al. [4]. Briefly, A𝛽
1−42
was dissolved
in hexafluoroisopropanol (HFIP, Sigma Aldrich) to 1mM;
HFIP was removed in vacuo. The peptide was suspended to
make a 5mM solution in dimethyl sulfoxide (DMSO, Sigma
Aldrich). The fibrillar form was prepared diluting the DMSO
stock solution of the peptide with a 100mMHEPES buffer to
a final concentration of 222𝜇M. The solution was incubated
at 37∘C for 7 days. After the aggregation period the sample
was centrifuged for 10min at 15000 g at room temperature.
The pellet containing the freshly prepared fibrillar A𝛽
1−42
was resuspended in 100mMHEPES buffer (pH 7.5) and used
in the experiment. The samples containing A𝛽 fibrils were
characterized by transmission electron microscope (Philips
CM10, FEI, Eindhoven, Figure 1).
2.3. Surgery. Rats were anaesthetized with an intraperitoneal
injection of a mixture of ketamine (10.0mg/0.1 kg) and
xylasine (0.8mg/0.1 kg). The animals were then placed in a
stereotaxic apparatus, a midline incision of the scalp was
made, the skin andmuscles were carefully retracted to expose
the skull, and a hole was drilled above the target area. The
solution was injected with a Hamilton syringe into the right
HC unilaterally at a rate of 1.0 𝜇L/min, beginning 2min after
the needle was lowered. The needle was removed very slowly
2min after the end of injection. The following coordinates
were used (from Bregma point): AP: −3.6; ML: −2.4; DV:
−2.8 [47]. Rats were randomly injected either with the
fibrillar form of A𝛽
1−42
(222𝜇MA𝛽
1−42
) or with vehiculum
(physiological saline). The A𝛽
1−42
-injected and the control
animals were treated with antibiotics and analgesics after the
surgery.
2.4. Spatial Navigation in the Morris Water Maze. Spatial
learning and memory were assessed in a Morris water maze
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(MWM) on days 14 to 20 after IHC fA𝛽
1−42
administration.
Behavioural testing was carried out in a room illuminated
by three lamps giving diffuse light of approximately equal
intensity at all points of the maze. The maze consisted of
a circular pool (𝑑 = 180 cm, ℎ = 60 cm) filled with water
(23 ± 1∘C) and made opaque with milk. A black curtain
was positioned around the pool with distal cues. A video
camera was mounted on the ceiling directly above the
test apparatus and relied to a video tracking system. The
behaviour of the animals was automatically recordedwith the
software EthoVision 2.3 (Noldus Information Technology,
The Netherlands, 2002).
Memory acquisition trials (training period) were per-
formed daily during the light phase, in blocks of 4, for 6 days
[4]. The pool was divided into four virtual quadrants, and an
invisible escape platform (diameter: 10 cm) was submerged in
themiddle of one of the four quadrants 1.5 cmbelow thewater
surface. At each trial, the rats were allowed to swim freely for
a maximum of 120 sec until they found the platform and were
then allowed to stay on it for 10 sec. If the rat failed to find the
platform within 120 sec, it was guided to or was placed on the
islandmanually for 10 sec.During the acquisition period, four
different starting points were used and the starting positions
were varied pseudorandomly over the trials. Twenty-four
hours after the last acquisition trial, retention was assessed
in a 120 sec probe trial, with the platform removed.
The data recorded by video tracking were used to calcu-
late the time to reach the platform, swim speed, and swim
path length (distance) during acquisition trials as well as
percent time spent in each of the 4 virtual quadrants and time
spent and number of crossings over the platform’s position
during the probe test.
2.5. Quantification of Dendritic Spine Density Using Golgi
Impregnation. FDRapidGolgiStainKit (FDNeuroTechnolo-
gies, Consulting & Services, Inc., USA) was used according
to the manufacturers’ instructions. Rats (𝑛 = 6, 3 per group)
were deeply anesthetized before the brain was removed from
the skull. The sacrificing was made after 29 days of the IHC
injection. The brains were removed quickly and handled
carefully to avoid damage of the tissue, and then tissue
blocks including hippocampus (approximately 0.7-0.8 cm)
were cut from the brain. The tissue blocks were immersed
in the impregnation solution (A + B solution) and stored
at room temperature for 2 weeks in the dark. After the first
impregnation period the brains were transferred into the
second solution (C) and stored at 4∘C in the dark for at least
48 hours.
100 𝜇m coronal sections were cut with a vibration micro-
tome (Zeiss Microm HM 650V) and were mounted on
gelatin coated glass slides. After the staining procedure (D, E
solution) and dehydration, the slides were coverslipped with
DPX mountant for histology (VWR International).
2.6. Quantitative Analysis. The Golgi sections were studied
by inverse light microscopy, using oil immersion objectives.
A total of 25 pyramidal neurons from the dorsoventral
hippocampalCA1 (stratum radiatum)were studied fromeach
of the 6 animals (75 dendritic shafts per groupwere analyzed).
The spine density of the proximal apical dendrite area was
analyzed (minimum 100𝜇m from soma). For each examined
neuron, one 100 𝜇m long segment from a second- or third-
order dendrite (protruding from its parent apical dendrite)
was chosen for spine density quantification as previously
described [48]. The dendrites were selected under a 100x oil
immersion lens and the images of these apical dendrites were
captured through a camera (AxioCam MRC V5, program:
AxioVision 40V. 4.8.1.0 Carl Zeiss Imaging SolutionsGmbH)
connected to a light microscope (Zeiss Observer Z1, with
10x ocular magnification) and a computer. Serial images
were made from each dendrite in the whole of the analyzed
segment (Z-stack). The captured multiple photomicrographs
fromone dendrite were then stacked into one file. To stack the
images and determine the spine density, ImageJ 1.44 software
(National Institute of Health, Bethesda, USA) was used.
2.7. Statistical Analysis. Behavioural data were analyzed by
repeated measures ANOVA, followed by Fisher’s LSD post
hoc tests for multiple comparisons. For the evaluation of the
results of Golgi impregnation, Student’s 𝑡-test for indepen-
dent samples was used. Statistical significance was set at 𝑃 <
0.05. The data were expressed as the means ± (S.E.M.).
3. Results
3.1. Spatial Learning and Memory in the Morris Water Maze.
MWMwas used to test spatial learning andmemory each day
on days 14 to 20 after IHC administration of fA𝛽
1−42
. Escape
latency to find the platformwas used as ameasure for evaluat-
ing spatial memory.The results showed that the performance
of both groups (fA𝛽-treated and untreated) improved from
day to day, reflecting long-term memory. However, learning
was slower each day in the fA𝛽
1−42
-treated compared to
the control group: escape latencies were significantly longer
in rats with fA𝛽
1−42
treatment than in the control animals
analysed by repeated measures ANOVA (𝐹
1,94
= 6.450; 𝑃 =
0.013) (Figure 2(a)). A significant difference was observed
between the groups also for swimming distance (repeated
measures ANOVA: 𝐹
1,94
= 6.840; 𝑃 = 0.010) (Figure 2(b)).
Despite the significantly slower learning in the fA𝛽
1−42
-
treated group, performance at the probe test (given 24 h
after the learning phase) indicated that spatial memory
was not impaired, as the time spent in quadrants and the
number of crossings over the virtual platform’s position were
comparable in the two groups (𝑡
22
= −1.247; 𝑃 = 0.226 and
𝑡
22
= 0.745; 𝑃 = 0.464, resp.) (Figures 3(a) and 3(b)).
3.2. Dendritic Spine Density. The Golgi staining method
labelled a subset of neurons in the hippocampus. In gen-
eral, 20–30 fully impregnated CA1 pyramidal cells could
be detected per slice. There was no difference between the
groups in staining.
We investigated all types of spines but solely focused
on determining dendritic spine density. Spine numerical
density was different between the two groups (t
28
= 14.415;
𝑃 < 0.0001). In the fA𝛽
1−42
-treated group decreasing
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Figure 2: fA𝛽
1−42
-injection induced learning deficit in the Morris water maze test. (a) fA𝛽
1−42
-injection resulted in slower learning during
the acquisition phase compared to control group (𝑃 = 0.013); (b) fA𝛽
1−42
-treated animals swam longer distance than the controls to find the
platform (𝑃 = 0.010). Each value represents the mean (±S.E.M.) (𝑛 = 12 rats per group).
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Figure 3: Injection of fA𝛽
1−42
did not affect performance in the Morris water maze probe test. (a) In the target quadrant, the amyloid-treated
animals spent time comparable to controls. (b) fA𝛽
1−42
-injection did not have a significant effect on the number of crossings over where the
virtual platform had been in the maze. Each value represents the mean (±S.E.M.) (𝑛 = 12 rats per group).
spine density (spine number) was detected compared to the
controls (Figure 4). Each column represents the mean value
of the dendritic spine number of 75-75 pyramidal neurons.
Photomicrographs of the pyramidal neurons from con-
trol, nontreated rats (Figures 5(a) and 6), and fA𝛽
1−42
-treated
rats (Figures 5(b) and 7) clearly demonstrate the difference in
dendritic spine density in the two experimental groups.
4. Discussion
The present study explored the effects of fA𝛽
1−42
on spatial
behaviour and on hippocampal dendritic spines in nontrans-
genic rats. A𝛽 accumulation in the specific brain regions is
a hallmark of AD pathology; however, the role of amyloid
plaques has been debated. Depositions of fA𝛽 in plaques
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Figure 4: Golgi staining revealed changes in spine density after the fA𝛽
1−42
-injection (A). Apical dendritic spine density analysis showed that
the amyloid treatment induced a decrease in spine density (𝑃 < 0.0001). In each experimental group 75 dendritic shafts of 3 animals were
studied. The values represent the mean (±S.E.M.) (𝑛 = 3 rats per group).
(a) (b)
Figure 5: Representative photomicrograph of a CA1 subfield pyramidal neuron from a control (a) and an amyloid-treated (b) rat.
and the surrounding oligomeric A𝛽 are considered as trigger
signals to induce dendritic spine loss and synapse dysfunction
in AD. A𝛽 assemblies are synaptotoxic: they can be bound to
axons and membrane proteins, resulting in Ca2+ influx into
the neurons [49]. The synapse and dendritic spine loss are
strongly correlated with cognitive impairment in AD, and A𝛽
has been shown to target synapses [40, 50].
Numerous studies have reported significant changes after
IHCadministration of various types and aggregation forms of
A𝛽 [4, 25–38]. Some studies reported that synapse dysfunc-
tion was triggered by A𝛽 oligomers [49, 51]. Other studies
proposed fA𝛽 deposits as causative factor for the local synap-
tic abnormalities since decrease of dendritic spine densitywas
detected nearby the A𝛽 plaques [13, 52–54]. However, it has
not been clear how the nondiffusible, immobile A𝛽 fibrils
interact with neuronal structure. As of today, senile plaques
are considered mostly as nontoxic “outburns” sequestering
toxic A𝛽 species to nontoxic fibrils. However, bilateral IHC
injection of fA𝛽
1−42
results in reduction of neuronal density
and increases of glial fibrillary acidic protein intensity, with
simultaneous appearance of numerous A𝛽 deposits and
behavioural performance deficits [4, 26]. IHC administration
of shorter form of A𝛽 (A𝛽
1−40
) results in decreased density of
dendritic spines in hippocampus [25, 28].
Our current findings demonstrated that synthetic fA𝛽
1−42
simultaneously decreased spatial learning abilitymeasured in
MWM (Figure 2(a)) and reduced dendritic spine density in
the rat hippocampus CA1 region (Figures 4–6). According
to the literature data, the synthetic fA𝛽 assemblies have also
a surrounding of A𝛽 oligomers [55], in accordance with the
law of chemical equilibriums. After fA𝛽 injection, diffusible
A𝛽 oligomers could be formed in the rat hippocampus and
initiate dendritic spine density loss. The measured spine loss
in HC CA1 region may explain the decreased learning ability
since the presence and maturation of dendritic spines on the
CA1 pyramidal cells are necessary to evolve the spatial mem-
ory unit [56]. It is generally accepted that misfolded proteins
initiate dendritic spine reduction and memory decline. A𝛽
and 𝛼-synuclein oligomers decrease the amount of synaptic
proteins and vesicles and via tau hyperphosphorylation
initiate the loss of dendritic spines [57, 58]. The instability
of dendritic spines leads to progressive neocortical spine loss
in a mouse model of Huntington’s disease [59]. Our results
support the theory that decreasing spine density in AD can
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(a) (b)
(c)
Figure 6: Representative photomicrographs of oblique dendritic segments from hippocampal CA1 pyramidal neurons of three control rats
((a), (b), and (c)). The dendritic spine density of vehiculum treated animals was significantly higher compared to the fA𝛽
1−42
-treated rats.
(1000x).
(a) (b)
(c)
Figure 7: Representative photomicrographs of oblique dendritic segments from hippocampal CA1 pyramidal neurons of every amyloid-
treated Golgi impregnated rat ((a), (b), and (c)). The fA𝛽
1−42
locally reduced the spine density in the fA𝛽
1−42
-injected group (1000x).
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cause or contribute to the memory decline: dendritic spines
are the site of most excitatory synapses and their loss is in
good correlation with the cognitive dysfunction.
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